Elsevier

Thrombosis Research

Volume 55, Issue 1, 1 July 1989, Pages 5-11
Thrombosis Research

Paper
Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis

https://doi.org/10.1016/0049-3848(89)90451-9Get rights and content

Abstract

Patients with symptoms of deep vein thrombosis for less than 10 days were treated with a standard dose of heparin. In the open label phase of the trial, 11 patients received 100 mg rt-PA on the first day and 50 mg on the subsequent day in an 8 hour infusion. In the double-blind phase, 8 patients were randomized to the same rt-PA regimen, 6 patients to an infusion of 50 mg rt-PA over 8 hours on days 1 and 2, and 7 patients to placebo infusions. The mean change in venographic score in all patients treated with rt-PA plus heparin is −3.8 units compared to −0.6 units in patients treated with heparin alone (p= 0.06). Bleeding complications classified as major were noted in 825 patients receiving the combined treatment.

References (8)

There are more references available in the full text version of this article.

Cited by (41)

  • Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report

    2021, Chest
    Citation Excerpt :

    The panel dyad reviewed 279 abstracts, from which they selected 45 full texts for review. Studies selected for abstraction and synthesis are detailed in Table 4.41-61 The panelists determined that the desirable effects of the intervention are moderate.

  • American society of hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism

    2020, Blood Advances
    Citation Excerpt :

    The use of thrombolysis should be rare for patients with DVT limited to veins below the common femoral vein. We identified 11 systematic reviews119-129 and 19 randomized trials (n = 1944).130-148 Trials included individuals with objectively confirmed symptomatic proximal DVT.

  • Thrombolytics for venous thromboembolic events: A systematic review with meta-analysis

    2020, Blood Advances
    Citation Excerpt :

    The 19 included trials were published between 1978 and 2017 and recruited 1956 patients (median of 48 patients per study) who had a mean age of 39.6 to 68.5 years, and the proportion of females ranged from 14.7% to 69.5% (Table 2). Twelve trials included patients with proximal DVT,40,42-46,51,52,54,56-58 1 trial included only patients with distal DVT,50 and in 6 trials, thrombus location or extension was not used as an inclusion or exclusion criterion.41,47-49,53,55 Although thrombolytics were infused systemically in most studies (n = 13), catheter-directed infusion was used in 4 studies, and local infusion in the dorsal pedal vein was used in 2 studies.

  • Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines

    2012, Chest
    Citation Excerpt :

    Remarks: Patients who are most likely to benefit from CDT (see text) and attach a high value to prevention of PTS and a lower value to the initial complexity, cost, and risk of bleeding with CDT are likely to choose CDT over anticoagulation alone. Many trials of systemic thrombolysis for the treatment of DVT assessed early lysis, often reported bleeding, but rarely reported recurrent VTE or development of PTS (Table S13 and S14).119–137 A meta-analysis138 summarized the findings of trials that assessed mortality, recurrent VTE, major bleeding, and PTS (Table 12, Table S15).

  • Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)

    2008, Chest
    Citation Excerpt :

    After successful CDT in patients with acute DVT, we recommend the same intensity and duration of anticoagulant therapy as for comparable patients who do not undergo CDT (Grade 1C). In 15 trials81,103-120 that randomized a total of 811 patients with acute DVT to systemic thrombolytic therapy or to anticoagulant therapy alone, as assessed by early repeat phlebography, systemic thrombolytic therapy achieved a higher frequency of complete or significant lysis (54% vs 4%) or partial lysis (18% vs 14%) [Table 4]. Three of the randomized trials reported postthrombotic symptoms after follow-up of 1.0 year,115 1.6 years,107 and 6.5 years103 (Table 4).

View all citing articles on Scopus
View full text